Oxford Biomedica (LON:OXB) Reaches New 52-Week High on Analyst Upgrade

Oxford Biomedica plc (LON:OXB) shares reached a new 52-week high during trading on Wednesday after Royal Bank Of Canada raised their price target on the stock from GBX 800 to GBX 930. Royal Bank Of Canada currently has an outperform rating on the stock. Oxford Biomedica traded as high as GBX 565 ($7.62) and last traded at GBX 556 ($7.50), with a volume of 612731 shares. The stock had previously closed at GBX 536.17 ($7.23).

Several other equities analysts have also commented on the company. Peel Hunt reiterated a “buy” rating and issued a GBX 451 target price on shares of Oxford Biomedica in a research note on Friday, August 1st. JPMorgan Chase & Co. lowered their price target on Oxford Biomedica from GBX 490 to GBX 400 and set a “neutral” rating for the company in a report on Tuesday, July 15th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Oxford Biomedica currently has an average rating of “Moderate Buy” and an average price target of GBX 540.25.

Insider Activity at Oxford Biomedica

In related news, insider Dame Kay Davies sold 4,563 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of GBX 500, for a total transaction of £22,815. Also, insider Roch Doliveux purchased 67,000 shares of the business’s stock in a transaction dated Friday, August 15th. The shares were purchased at an average cost of GBX 450 per share, with a total value of £301,500. 21.17% of the stock is currently owned by insiders.

Oxford Biomedica Price Performance

The stock’s 50-day moving average is GBX 400.15 and its 200-day moving average is GBX 341.65. The firm has a market cap of £591.03 million, a P/E ratio of -4.13 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.